Adriaan J. van der Meer

TL;DR: The use of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance.

TL;DR: The global estimate of viraemic HCV infections is lower than previous estimates, largely due to more recent prevalence estimates in Africa, and increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections.

TL;DR: Among patients with chronic HCV infection and advanced hepatic fibrosis, sustained virological response to interferon-based treatment was associated with lower all-cause mortality.

TL;DR: The estimate of HBV prevalence in 2016 differs from previous studies, potentially because it took into account the effect of infant prophylaxis and early childhood vaccination, as well as changing prevalence over time.

TL;DR: Patients with HCV-induced cirrhosis and SVR showed an annual risk of approximately 1% for HCC and 2% for clinical disease progression, therefore, to prevent HCC surveillance, chronic HCV infection should preferably be treated before Cirrhosis has developed.